作者
Claudio R Scafoglio, Brendon Villegas, Gihad Abdelhady, Sean T Bailey, Jie Liu, Aditya S Shirali, W Dean Wallace, Clara E Magyar, Tristan R Grogan, David Elashoff, Tonya Walser, Jane Yanagawa, Denise R Aberle, Jorge R Barrio, Steven M Dubinett, David B Shackelford
发表日期
2018/11/14
期刊
Science translational medicine
卷号
10
期号
467
页码范围
eaat5933
出版商
American Association for the Advancement of Science
简介
The diagnostic definition of indeterminate lung nodules as malignant or benign poses a major challenge for clinicians. We discovered a potential marker, the sodium-dependent glucose transporter 2 (SGLT2), whose activity identified metabolically active lung premalignancy and early-stage lung adenocarcinoma (LADC). We found that SGLT2 is expressed early in lung tumorigenesis and is found specifically in premalignant lesions and well-differentiated adenocarcinomas. SGLT2 activity could be detected in vivo by positron emission tomography (PET) with the tracer methyl 4-deoxy-4-[18F] fluoro-alpha-d-glucopyranoside (Me4FDG), which specifically detects SGLT activity. Using a combination of immunohistochemistry and Me4FDG PET, we identified high expression and functional activity of SGLT2 in lung premalignancy and early-stage/low-grade LADC. Furthermore, selective targeting of SGLT2 with FDA …
引用总数
201920202021202220232024141737202224
学术搜索中的文章